Stroke prevention with rivaroxaban in higher‐risk populations with atrial fibrillation

BACKGROUND: Atrial fibrillation (AF), the most common cardiac arrhythmia, is a major risk factor for stroke. Rivaroxaban, an oral factor Xa inhibitor, is approved for the prevention of stroke in patients with non‐valvular AF. In the pivotal phase III trial ROCKET AF, rivaroxaban demonstrated non‐inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Diener, H.‐C., Halperin, J. L., Fox, K., Hankey, G. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Cardiovascular
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681170/
https://www.ncbi.nlm.nih.gov/pubmed/25854636
http://dx.doi.org/10.1111/ijcp.12631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681170/
https://www.ncbi.nlm.nih.gov/pubmed/25854636
http://dx.doi.org/10.1111/ijcp.12631

Ejemplares similares